Skip to main content
. 2016 Apr 4;113(16):4458–4463. doi: 10.1073/pnas.1600996113

Table 3.

Comparison of survival benefit of candidate JUNV therapeutics in the guinea pig model

Treatment Timing of first dose with respect to challenge Dose (per kg) Dose frequency Survival in treated Survival in controls Ref.
Ribavirin +4 h 60 mg Daily for 24 d 3/6 0/5 7
Favipiravir +1 d 300 mg (oral) 2x/day for 14 d 2/10 0/10 8
+2 d 300 mg 2x/day for 14 d 7/9 1/9
Cyclophosphamide +3 d 50/25 mg +3 d/+10 d 3/18 0/18 6
Convalescent serum +6 d 30,000 TU* Once 6/6 0/20 9
J199 +6 d 25 mg +6/+10 d 6/6 0/3
+7 d 25 mg +7/+11 d 11/12 0/9
*

No less then 3,000 TU/kg is the recommended clinical dose (4). Dosing and challenge are all i.p. unless otherwise noted. Data are not comprehensive but rather highlight the best efficacy demonstrated by the treatment. Antibody-based treatments are highlighted in bold.